Ahammune Biosciences, an innovative biotech firm focused on dermatological therapies, has successfully raised $5 million in a Series A funding round led by the early-stage venture capital firm
Ahammune Biosciences, an innovative biotech firm focused on dermatological therapies, has successfully raised $5 million in a Series A funding round led by the early-stage venture capital firm pi Ventures. This funding round also welcomed participation from Capital2B, Colossa Ventures, Bipin Agarwal, Unicornus Maximus LLP, along with existing investors such as Ideaspring Capital, Kotak Alternate Assets, Legacy Assets LLP, and the Indian Angel Network (IAN).
The newly acquired capital will primarily be allocated to conducting Phase II human clinical trials for Ahammune’s lead drug candidate targeting vitiligo, a chronic skin condition characterized by the loss of skin pigmentation. Dr. Parul Ganju, Co-founder of Ahammune, shared with YourStory that while the complete Phase II trial is projected to span about two years, preliminary results may be available sooner.
Dr. Ganju emphasized the urgent need for effective treatments for vitiligo, stating, “There is a big gap in the market for a cost-effective, safe, and effective drug.” The company’s drug is notable for its first-in-class mechanism, offering a competitive edge in the crowded dermatological landscape.
In addition to advancing clinical trials, Ahammune plans to expand its patent portfolio around its proprietary technology—a small molecule therapeutics platform. This platform is designed to target cellular processes that influence skin health and immunity, not just for vitiligo but also for other immune-mediated skin diseases.
Dr. Ganju indicated that the company is actively developing a pipeline of patented molecules aimed at treating various dermatological and autoimmune conditions. “Post Phase II trial, we are considering two options: a larger fundraising round for commercialization after completing Phase III trials or seeking partners to co-develop our drug candidate for the global market,” she stated.
With this funding, Ahammune is now positioned to sustain its research and development activities for the next two years. This financial runway is crucial for the firm as it aims to solidify its position as a leader in drug discovery within the dermatological sector.
Founded in 2016 by Dr. Ganju and Dr. Krishnamurthy Natarajan, Ahammune is on a mission to tackle skin conditions that affect millions worldwide. The company’s commitment to addressing unmet medical needs sets it apart in a competitive landscape.
Roopan Aulakh, Managing Director at pi Ventures, highlighted the significance of Ahammune’s approach to vitiligo treatment. She noted that the drug’s innovative mechanism provides a substantial competitive advantage. While she did not disclose the specific investment amount from pi Ventures, Aulakh confirmed that the firm’s contribution was under 50% of the total funding raised.
Ahammune Biosciences is poised for significant advancements in the treatment of vitiligo and other skin conditions, backed by its recent $5 million funding. As the company moves forward with clinical trials and patent expansions, it aims to fill critical gaps in the dermatological market, potentially changing the lives of millions suffering from skin disorders.
